Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome

Natsumi Matsuura, Chiharu Asano, Kai Nagasawa, Shogo Ito, Yusuke Sano, Yuji Minagawa, Yuichiro Yamada, Takuya Hattori, Shogo Watanabe, Toyoaki Murohara, Kohzo Nagata

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background Pioglitazone is a thiazolidinedione drug that acts as an insulin sensitizer. We recently characterized DahlS.Z-Leprfa/Leprfa (DS/obese) rats, derived from a cross between Dahl salt-sensitive and Zucker rats, as a new animal model of metabolic syndrome. We have now investigated the effects of pioglitazone on cardiac and adipose tissue pathology in this model. Methods and results DS/obese rats were treated with pioglitazone (2.5 mg/kg per day, per os) from 9 to 13 weeks of age. Age-matched homozygous lean (DahlS.Z-Lepr+/Lepr+, or DS/lean) littermates served as controls. Pioglitazone increased body weight and food intake in DS/obese rats. It also ameliorated left ventricular (LV) hypertrophy, fibrosis, and diastolic dysfunction as well as attenuated cardiac oxidative stress and inflammation, without lowering blood pressure, in DS/obese rats, but it had no effect on these parameters in DS/lean rats. In addition, pioglitazone increased visceral and subcutaneous fat mass but alleviated adipocyte hypertrophy and inflammation in visceral adipose tissue in DS/obese rats. Furthermore, pioglitazone increased the serum concentration of adiponectin, induced activation of AMP-activated protein kinase (AMPK) in the heart, as well as ameliorated glucose intolerance and insulin resistance in DS/obese rats. Conclusions Treatment of DS/obese rats with pioglitazone exacerbated obesity but attenuated LV hypertrophy, fibrosis, and diastolic dysfunction, with these latter effects being associated with the activation of cardiac AMPK signaling likely as a result of the stimulation of adiponectin secretion.

Original languageEnglish
Pages (from-to)360-369
Number of pages10
JournalInternational Journal of Cardiology
Volume179
DOIs
Publication statusPublished - Jan 20 2015
Externally publishedYes

Fingerprint

pioglitazone
Adipose Tissue
Pathology
AMP-Activated Protein Kinases
Intra-Abdominal Fat
Adiponectin
Left Ventricular Hypertrophy
Fibrosis
Inbred Dahl Rats
Inflammation
Zucker Rats
Glucose Intolerance
Subcutaneous Fat
Adipocytes
Hypertrophy

Keywords

  • Adipose tissue
  • Cardiac remodeling
  • Glucose metabolism
  • Inflammation
  • Metabolic syndrome
  • Thiazolidinedione

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. / Matsuura, Natsumi; Asano, Chiharu; Nagasawa, Kai; Ito, Shogo; Sano, Yusuke; Minagawa, Yuji; Yamada, Yuichiro; Hattori, Takuya; Watanabe, Shogo; Murohara, Toyoaki; Nagata, Kohzo.

In: International Journal of Cardiology, Vol. 179, 20.01.2015, p. 360-369.

Research output: Contribution to journalArticle

Matsuura, N, Asano, C, Nagasawa, K, Ito, S, Sano, Y, Minagawa, Y, Yamada, Y, Hattori, T, Watanabe, S, Murohara, T & Nagata, K 2015, 'Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome', International Journal of Cardiology, vol. 179, pp. 360-369. https://doi.org/10.1016/j.ijcard.2014.11.099
Matsuura, Natsumi ; Asano, Chiharu ; Nagasawa, Kai ; Ito, Shogo ; Sano, Yusuke ; Minagawa, Yuji ; Yamada, Yuichiro ; Hattori, Takuya ; Watanabe, Shogo ; Murohara, Toyoaki ; Nagata, Kohzo. / Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. In: International Journal of Cardiology. 2015 ; Vol. 179. pp. 360-369.
@article{327741da868a4067ad84091278832a86,
title = "Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome",
abstract = "Background Pioglitazone is a thiazolidinedione drug that acts as an insulin sensitizer. We recently characterized DahlS.Z-Leprfa/Leprfa (DS/obese) rats, derived from a cross between Dahl salt-sensitive and Zucker rats, as a new animal model of metabolic syndrome. We have now investigated the effects of pioglitazone on cardiac and adipose tissue pathology in this model. Methods and results DS/obese rats were treated with pioglitazone (2.5 mg/kg per day, per os) from 9 to 13 weeks of age. Age-matched homozygous lean (DahlS.Z-Lepr+/Lepr+, or DS/lean) littermates served as controls. Pioglitazone increased body weight and food intake in DS/obese rats. It also ameliorated left ventricular (LV) hypertrophy, fibrosis, and diastolic dysfunction as well as attenuated cardiac oxidative stress and inflammation, without lowering blood pressure, in DS/obese rats, but it had no effect on these parameters in DS/lean rats. In addition, pioglitazone increased visceral and subcutaneous fat mass but alleviated adipocyte hypertrophy and inflammation in visceral adipose tissue in DS/obese rats. Furthermore, pioglitazone increased the serum concentration of adiponectin, induced activation of AMP-activated protein kinase (AMPK) in the heart, as well as ameliorated glucose intolerance and insulin resistance in DS/obese rats. Conclusions Treatment of DS/obese rats with pioglitazone exacerbated obesity but attenuated LV hypertrophy, fibrosis, and diastolic dysfunction, with these latter effects being associated with the activation of cardiac AMPK signaling likely as a result of the stimulation of adiponectin secretion.",
keywords = "Adipose tissue, Cardiac remodeling, Glucose metabolism, Inflammation, Metabolic syndrome, Thiazolidinedione",
author = "Natsumi Matsuura and Chiharu Asano and Kai Nagasawa and Shogo Ito and Yusuke Sano and Yuji Minagawa and Yuichiro Yamada and Takuya Hattori and Shogo Watanabe and Toyoaki Murohara and Kohzo Nagata",
year = "2015",
month = "1",
day = "20",
doi = "10.1016/j.ijcard.2014.11.099",
language = "English",
volume = "179",
pages = "360--369",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome

AU - Matsuura, Natsumi

AU - Asano, Chiharu

AU - Nagasawa, Kai

AU - Ito, Shogo

AU - Sano, Yusuke

AU - Minagawa, Yuji

AU - Yamada, Yuichiro

AU - Hattori, Takuya

AU - Watanabe, Shogo

AU - Murohara, Toyoaki

AU - Nagata, Kohzo

PY - 2015/1/20

Y1 - 2015/1/20

N2 - Background Pioglitazone is a thiazolidinedione drug that acts as an insulin sensitizer. We recently characterized DahlS.Z-Leprfa/Leprfa (DS/obese) rats, derived from a cross between Dahl salt-sensitive and Zucker rats, as a new animal model of metabolic syndrome. We have now investigated the effects of pioglitazone on cardiac and adipose tissue pathology in this model. Methods and results DS/obese rats were treated with pioglitazone (2.5 mg/kg per day, per os) from 9 to 13 weeks of age. Age-matched homozygous lean (DahlS.Z-Lepr+/Lepr+, or DS/lean) littermates served as controls. Pioglitazone increased body weight and food intake in DS/obese rats. It also ameliorated left ventricular (LV) hypertrophy, fibrosis, and diastolic dysfunction as well as attenuated cardiac oxidative stress and inflammation, without lowering blood pressure, in DS/obese rats, but it had no effect on these parameters in DS/lean rats. In addition, pioglitazone increased visceral and subcutaneous fat mass but alleviated adipocyte hypertrophy and inflammation in visceral adipose tissue in DS/obese rats. Furthermore, pioglitazone increased the serum concentration of adiponectin, induced activation of AMP-activated protein kinase (AMPK) in the heart, as well as ameliorated glucose intolerance and insulin resistance in DS/obese rats. Conclusions Treatment of DS/obese rats with pioglitazone exacerbated obesity but attenuated LV hypertrophy, fibrosis, and diastolic dysfunction, with these latter effects being associated with the activation of cardiac AMPK signaling likely as a result of the stimulation of adiponectin secretion.

AB - Background Pioglitazone is a thiazolidinedione drug that acts as an insulin sensitizer. We recently characterized DahlS.Z-Leprfa/Leprfa (DS/obese) rats, derived from a cross between Dahl salt-sensitive and Zucker rats, as a new animal model of metabolic syndrome. We have now investigated the effects of pioglitazone on cardiac and adipose tissue pathology in this model. Methods and results DS/obese rats were treated with pioglitazone (2.5 mg/kg per day, per os) from 9 to 13 weeks of age. Age-matched homozygous lean (DahlS.Z-Lepr+/Lepr+, or DS/lean) littermates served as controls. Pioglitazone increased body weight and food intake in DS/obese rats. It also ameliorated left ventricular (LV) hypertrophy, fibrosis, and diastolic dysfunction as well as attenuated cardiac oxidative stress and inflammation, without lowering blood pressure, in DS/obese rats, but it had no effect on these parameters in DS/lean rats. In addition, pioglitazone increased visceral and subcutaneous fat mass but alleviated adipocyte hypertrophy and inflammation in visceral adipose tissue in DS/obese rats. Furthermore, pioglitazone increased the serum concentration of adiponectin, induced activation of AMP-activated protein kinase (AMPK) in the heart, as well as ameliorated glucose intolerance and insulin resistance in DS/obese rats. Conclusions Treatment of DS/obese rats with pioglitazone exacerbated obesity but attenuated LV hypertrophy, fibrosis, and diastolic dysfunction, with these latter effects being associated with the activation of cardiac AMPK signaling likely as a result of the stimulation of adiponectin secretion.

KW - Adipose tissue

KW - Cardiac remodeling

KW - Glucose metabolism

KW - Inflammation

KW - Metabolic syndrome

KW - Thiazolidinedione

UR - http://www.scopus.com/inward/record.url?scp=84920643340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920643340&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2014.11.099

DO - 10.1016/j.ijcard.2014.11.099

M3 - Article

VL - 179

SP - 360

EP - 369

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -